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Objective: We previously demonstrated that calcium can be harmful to the 
hypoxic neonatal heart. Despite the fact that magnesium inhibits mem- 
brane transport of calcium, few studies have examined whether magnesium 
can prevent the deleterious effects of calcium in cardioplegic solutions. 
Methods: Twenty neonatal piglets (5 to 18 days old) underwent 60 minutes 
of ventilator hypoxia (inspired oxygen fraction 8% to 10%) followed by 
reoxygenation with the use of cardiopulmonary b pass before cardioplegic 
arrest to produce a clinically relevant hypoxic "stress" injury. The aorta 
was then crossclamped for 70 minutes with multidose blood cardioplegia. 
Ten piglets received a hypocalcemic (0.2 to 0.4 mmol/L) cardioplegic 
solution without (groUp 1, n = 5) or with magnesium (10 mEq/L) (group II, 
n = 5) supplementation. Ten other piglets were protected with a normo- 
caleemic (1.0 to 1.2 mmol/L) cardioplegic solution without (group III, n = 
5) or with magnesium (group IV, n = 5). Myocardial function was assessed 
by means of pressure volume loops and expressed as a Percentage of 
control. Coronary vascular esistance was assessed uring each cardiople- 
gic infusion. Results: Adding magnesium to a hypocalcemic cardioplegic 
solution (groups I and II) had no effect: Both groups had complete 
preservation of postbypass systOlic function (end-systolic elastance 101% vs 
104%) and preload recruitable stroke work (101% vs 102%), minimal 
increase in diastolic stiffness (159% vs i53%), and no difference in 
myocardial tissue edema (78.8% vs 78.9%) or coronary vascular esistance. 
Conversely~ when a normocalcemic cardioplegic solution was administered 
without magnesium supplementation (group III), the results were markedly 
poorer than results obtained with magnesium Supplementation (group IV). 
Without magnesium, there was a marked reduction in postbypass systolic 
function (end-systolic elastance 49% vs 101%;p < 0.05), increased iastolic 
stiffness (276% vs 162%; p < 0.05), decreased preload recruitable stroke 
work (53% vs 102%; p < 0.05), increased myocardial tissue edema (80.0% 
Vs 78.9%; p < 0.05), and a rise in coronary vascular esistance (p < 0.05). 
Magnesium supplementation f the normocalcemic cardioplegic solution, 
by contrast, resulted in complete functional recovery. Conclusions: This 
study demonstrates that (1) magnesium does not alter the cardioprotective 
effects of a hypocalcemi c cardioplegiC solution, (2) a normocalcemic 
cardioplegic solution is detrimental to neonatal myocardium subjected to a 
previous hypoxic stress, and (3) magnesium supplementation f normocal- 
cemic cardioplegic solutions prevents the deleterious effects of calcium. 
(J Thorac Cardiovasc Surg 1997;114:1010-9) 
From the Division of Cardiothoracic Surgery at the University of 
Illinois at Chicago, Chicago, Ill. 
Read at the Seventy-seventh Annual Meeting of The American 
Association for Thoracic Surgery, Washington, D.C., May 4-% 
199% 
Received for publiczition May 7, 1997; revisions requested June 
25, 1997; revisions received August 11, 1997; accepted for 
publication August 12, 1997. 
l o~o 
Address for reprints: Bradley S. Allen, MD, Cardiothoracic 
Surgery Division, Suite 417 CSB (M/C 958), University of 
Illinois at Chicago, 840 South Wood St., Chicago, IL 60612- 
7323. 
*Supported in part by the Pillsbury Fellowship. 
Copyright © 1997 by Mosby-Year Book, Inc. 
0022-5223/97 $5.00 + 0 12/6/85366 
The Journal of Thoracic and 
CardiovasCular Surgery 
Volume 114, Number 6 
Kronon et al. 1011 
W el have shown the superiority of hypocalcemic 
blood Cardioplegic solutions in protecting hy- 
poxic neonatal hearts. However, in clinical practice, 
there are often transient fluxes in the ionized cal- 
cium concentration of the cardioplegic solution be- 
cause of variability in pH, hemodilution, tempera- 
ture, potassium, and systemic calcium levels. The 
ischemic neonatal my0cardium is therefore at risk of 
exposure to potentially higher or lower calcium 
levels than originally intended, which may increase 
the risk of a calcium-mediated injury. This unin- 
tended transient calcium rise assumes even greater 
impOrtance in pediatric myocardial protection, be- 
cause immature myocytes are less able to handle a 
given calcium load than is the adult myocardium. 2' 3 
In addition, despite concerns over calcium injury, 
many pediatric surgeons continue to use normocal- 
cemic cardioplegic solutions. Although magnesium 
has been shown to inhibit calcium membrane trans- 
port and thus prevent its intracellular accumulation 
in adults, few studies have examined the relationship 
of calcium and magnesium in neonatal myocardial 
protection. 4-7 However, if magnesium inhibits cal- 
cium influx, it may prevent the injury that occurs 
from exposure of the ischemic myocardial cell to 
these higher calcium concentrations. 
In view of the unique structural, functional, and 
metabolic haracteristics of the neonatal heart, myo- 
cardial protective strategies and cardioplegic solu- 
tions must be studied in the infant heart if results are 
to be clinically applicable. Inclusion of stressed 
(hypoxic) hearts in any investigation of pediatric 
myocardial protection is also critically important, 
because Calcium homeostasis becomes even more 
significant when the infant myocardium is altered by 
a preoperative stress such as hypoxiaJ' 3 This study 
therefore examines the relationship between cal- 
cium and magnesium in cardioplegic solutions with 
the use of an intact in vivo model that mimics the 
clinical conditions of the operating room in hypoxic 
(stressed) neonatal hearts. 
Materials and methods 
Twenty neonatal (5- to 18-day-old) piglets (3.5 to 5 kg) 
were premedicated intramuscularly with ketamine, 40 
mg/kg, and anesthetized with pentobarbital, 30 mg/kg 
intraperitoneaily followed by 5 mg/kg intravenously each 
hour. The lungs were ventilated via a tracheotomy by 
means of a volume ventilator (Servo 900B, Siemens/ 
Elema, Solna, Sweden). All animals received humane care 
in compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the National Academy 
of Sciences and published by the National institutes of 
Health (NIH publication No. 96-03, revised 1996). 
The femoral artery and vein were cannulated to moni- 
tor arterial pressure, for blood gas determinations, and for 
intravenous infusions. After left thoracotomy, the Coro- 
nary sinus was cannulated for blood sampling and pres- 
sure monitoring via the ligated hemiazygos vein. The 
heart Was exposed via a median stern0tomy~ and trans- 
ducer-tipped catheters (Millar Instruments, Inc,, Hous- 
ton, Tex:) were placed into the left ventricle, thoracic 
aorta (via the internal thoracic artery), left atrium, and 
pulmonary artery. The signals were routed to a recorder 
(model 4586C, Hewlett-Packard Company, Palo Alto, 
Calif.) by means of signal conditioners (model 8805C, 
Hewlett-Packard). A conductance atheter equipped with 
eight electrodes (Webster Laboratories, Baldwin Park, 
Calif.) was inserted through the left ventricular (LV) apex 
and the signals routed to a Sigma-5 dual-field signal 
conditioner processor (Leycon Cardiodynamics, Leiden, 
The Netherlands). After systemic heparinization (3 mg/ 
kg), a thin-walled venous cannuia (18F) and an aortic 
cannula (8F) were inserted into the right atrial appendage 
and left subclavian artery, respectively, An 18-gauge car- 
dioplegia needle (DLP, Inc., Grand Rapids, Mich.) was 
inserted into the aortic root for delivery of cardioplegic 
solutions. Arterial blood gases , electrolytes, and hemoglo- 
bin levels (Blood Gas System 288, Ciba Coming, Med- 
field, Mass.) were measured every 15 minutes to ensure 
optimal evels. A heating blanket was placed below the 
piglet, and a heating pad was placed on the abdomen to 
maintain a constant core temperature of 37 ° to 38 ° C. 
External heat sources were discontinued uring systemic 
cooling. The cardiOpulmonary b pass (CPB) Circuit was 
heparinized, primed with packed red Cells from donor 
pigs, and made normocalcemic with calcium chloride. The 
hematocrit value was adjusted to 25% to 35% with 0.9% 
normal saline solution. A Baxter Univox membrane oxy- 
genator (Baxter Healthcare Corporation, Irvine, Calif.) 
was used, and the systemic flow was adjusted to approxi- 
mately 100 ml/kg per minute to maintain a continuously 
monitored aortic root pressure of 30 to 50 mm Hg. 
Cardioplegia protocol. Cardioplegic solutions (CAPS 
Service, Research Medical Inc., Salt Lake City, Utah) are 
shown in Tables I and II. The aorta was crossclamped for 
70 minutes and cardioplegic solution delivered by means 
of a protocol of 5 minutes of warm (37 ° C) followed by 5 
minutes of cold (4 ° C) blood cardioplegic induction, a 
2-minute cold (4 ° C) multidose cardioplegic nfusion every 
20 minutes, and a 4-minute warm (37 ° C) cardioplegic 
reperfusate ("hot shot") before aortic unclamping. Car- 
di0plegic solution was infused at a continuously measured 
aortic pressure of 40 to 50 mm Hg. immediately after the 
aorta was crossclamped all piglets were cooled to a 
systemic temperature of 25 ° C, and rewarming to 37°C 
was initiated 16 minutes before aortic unclamping. All 
piglets were weaned from CPB with no inotropic support 
30 minutes after aortic unclamping. Final functional and 
biochemical measurements were made 30 minutes later, 
after arterial blood gases and calcium and potassium 
levels were normalized. 
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Table  I. Warm blood cardioplegic solution 
Cardioplegia Volume Component Concentration 
additive added (ml) modified delivered* 
KC1 (2 mEq/ml) 10 K + 8-10 mEq/L 
Tham (0.3 mol/L) 225 pH pH 7.5-7.7 
CPD 225 Ca +2 0.2-0.3 mmol/Lt 
MgC12 (2 mEq/ml) 24 Mg +2 10-12 mEq/L~ 
Asparatate/glutamate 250 Substrate 13 mmol/L each 
Ds0W 40 Glucose <400 mg/dl 
Ds0W 200 Osmolarity 380-400 mOsm 
Tham, Tromethamine; CPD, citrate-phosphate-dextrose; Ds  W, 50% dex- 
trose in water. 
*When mixed in a 4:1 ratio with blood. 
?For normocaleemic cardioplegia, CaCI2 was added to make the ionized 
Ca +2 1.1 to 1.3/zmol/L when mixed in a 4:1 ratio with blood. 
~MgC12 was added only to groups II and IV (magnesium enrichment); 
groups I and III received the same solution except no MgCI 2 was added. 
Experimental groups. All piglets underwent 60 minutes 
of ventilator hypoxia by lowering the fraction of inspired 
oxygen to 8% to 10%, producing an arterial oxygen 
tension of 25 to 35 mm Hg and an arterial oxygen 
saturation of 65% to 70%. Before hypoxemia, piglets were 
given transfusions as necessary to increase their hemato- 
crit value to greater than 35%. This simulates the chronic 
adaptive change of erythrocytosis, which increases oxygen- 
carrying capacity, thus allowing ischemia to be avoided 
during hypoxia. At the end of 60 minutes all piglets were 
subjected to CPB at an inspired oxygen fraction of 100% 
for 5 minutes to produce a reoxygenation i jury. 1" s, 9 Ten 
piglets were subjected to this cardioplegia protocol with a 
hypocalcemic (0.2 to 0.4 retool/L) Cardioplegic solution. In 
five (group I) no exogenous magnesium was added to the 
eardioplegic solution, and in the other five (group II) 
magnesium was added to produce a concentration of 
approximately 10 mEq/L when mixed in a 4:1 ratio with 
blood. In 10 other piglets, calcium chloride was added to 
the cardioplegic solutions to make the ionized calcium 
concentration normal (1.0 to 1.2 mmol/L) when mixed 
with blood in a 4:1 ratio. Five of these hearts were 
protected with solutions containing no magnesium (group 
III), and five received magnesium enrichment (group IV). 
Myocardial performance. LV pressure and conduc- 
tance catheter signals were amplified and digitized to 
inscribe LV pressure volume loops after first correcting 
for paiallel conductance (myocardial tissue and blood 
viscosity) with the use of hypertonic saline solution ac- 
cording to the method of Baan, Van Der  Velde, and 
Steendijk. 1° A series of pressure volume loops was gener- 
ated under varying conditions by transient occlusion of the 
inferior vena cava during an 8-second period of apnea. 
Measurements were made before hypoxia (baseline) and 
30 minutes after CPB was discontinued. 
The end-systolic and end-diastolic pressure volume 
relationships and the preload recruitable stroke work 
(PRSW) relationship were analyzed with the use of a 
computer graphics program (Spectrum, Bowman-Gray 
School of Medicine, Winst0n-Salem, N.C.) on a 486-33 
mHz Dell personal computer. LV systolic performance 
Table I I .  Cold blood cardioplegic solution 
Cardioplegia Volume Component Concentration 
additive added (ml) modified delivered* 
KC1 (2 rnEq/ml) 10 K + 8-10 mEq/L 
Tham (0.3 tool/L) 200 pH pH 7.6-7.8 
CPD 50 Ca +2 0.5-0.6 mmol/Lt 
MgC12 (2 mEq/ml) 18 Mg +2 10-12 mg/L$ 
Ds0W 550 Osmolarity 340-360 mOsrn 
Tham, Tromethamine; CPD, citrate-phosphate-dextrose; Ds  W, 50% dex- 
trose in water. 
*When mixed in a 4:1 ratio with blood. 
?For normocalcemic cardioplegia, CaCI2 was added to make the ionized 
Ca +z L1 to 1.3 txmol/L when mixed in a 4:1 ratio with blood. 
SMgCI2 was added only to groups II and IV (magnesium enrichment); 
groups I and III received the same solution except no MgC12 was added. 
was determined from the descending slope of the end- 
systolic pressure volume relationship by means of linear 
regression analysis and designated as end-systolic elas- 
tance. End-diastolic ompliance was determined from the 
exponential regression of the end-diastolic pressure vol- 
ume relationship. Overall myocardial performance was 
assessed by PRSW, which was calculated as the integral of 
LV transmural pressure and cavity volume over each 
cardiac cycle. Functional measurements were expressed as 
percent recovery of baseline values with each piglet acting 
as its own control. After final hemodynamic measure- 
ments, all piglets were again subjected to CPB and cooled 
to 25 ° C. Hearts were then arrested with cold (4 ° C) blood 
cardioplegic solution and transmural LV biopsy speci- 
mens were obtained. Endocardial and epicardial portions 
were separated, frozen quickly in liquid nitrogen, and 
stored for biochemical analysis. Separate samples were 
obtained to measure myocardial water. 
Physiologic measurements. Coronary vascular resis- 
tance (CVR) was determined uring each cardioplegic 
infusion by measuring coronary sinus pressure and car- 
dioplegic flow once a constant infusion rate with an aortic 
root pressure between 40 and 50 mm Hg was achieved. 
CVR was calculated by means of the following formula: 
CVR (dynes/sec/cm -5) - 
CIP - CSP 
CFR 
× 80 
where CIP = cardioplegia infusion pressure, CSP = 
coronary sinus pressure, and CFR = cardioplegia flow 
rate. 
Biochemical analysis. Myocardial samples were 
crushed in a liquid nitrogen-cooled mortar and pestle and 
lyophilized (Savant Speed Vac Systems, Farmingdale, 
N.Y.). The adenosine pool was determined according to 
the method of Sarin and associates. 11 A 10 to 15 mg 
sample of dry tissue was extracted with 0.6 mol/L perchlo- 
ric acid, the protein-free supernatant neutralized by a 
mixture of KHCO3 in 0.5 mol/L Tris buffer (pH 7.5), and 
a neutralized solution allowed to stand at 4 ° C to precip- 
itate KCLO 4. Aliquots of the neutralized extract were 
chromatographed with the use of a high-performance 
liquid chromatography device (Waters, Inc., Milford, 
Mass.) equipped with a Waters Nova-Pak column. The 
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Fig. 1. LV systolic function as measured by the end-systolic elastance (EES) and expressed as a percentage 
of baseline values. Systolic function is completely preserved, independent of the presence of magnesium, 
in hearts protected with a hypocalcemic cardioplegic solution. Hearts protected with a normocalcemic 
cardioplegic solution alone exhibited marked loss of systolic function. In contrast, magnesium enrichment 
of the normocalcemic cardioplegic solution offset he detrimental effects of high levels of calcium, resulting 
in complete return of systolic function. *p < 0.001. 
adenosine pool was isocratically eluted with a mobile 
phase consisting of ammonium phosphate, 0.1 mmol/L, 
and tetrabutylammonium hydroxide, 0.5 nmol/L (pH 5.0), 
and detected at 233 nm. Adenosine triphosphate (ATP) 
and diphosphate (ADP) levels were expressed as micro- 
grams per gram of dry tissue. 
Myocardial water. Ventricular samples were placed in 
preweighed vials and dried to a constant weight at a 
temperature of 85 ° C. The percent myocardial water was 
calculated by means of the formula: 
Wet weight - Dry weight 
% Myocardial water = Wet weight × 100 
Statistics. Data were analyzed with the use of JMP 
V2.0 software (SAS Institute, Inc., Cary, N.C.) on a 
Macintosh IIVX computer (Apple Inc., Cupertino, Cal- 
if.). Group data are expressed as mean _+ standard error 
of the mean. Paired Student's t test and two-way analysis 
of variance with interaction (factorial analysis) were used 
for comparison of variables among experimental groups. 
If the analysis of variance revealed a significant interac- 
tion, a pairwise test of individual group means was con- 
trasted by way of multiple comparisons (Tukey's test), 
using a level of significance ofp < 0.05. 
Results 
The groups did not differ with regard to prebypass 
baseline values of LV contractility (end-systolic elas- 
tance 33 +_ 1), diastolic compliance (0.03 _+ 0.01), or 
PRSW (75 _+ 3). Hypoxia resulted in an increase in 
heart rate from 130 to 150 beats/min to 190 to 220 
beats/min, a decrease in systemic vascular resis- 
tance, and an increase in pulmonary vascular esis- 
tance, but it did not significantly affect cardiac 
output. All piglets tolerated 60 minutes of hypoxia 
with stable hemodynamics. 
Hemodynamic and physiologic measurements. 
Results are depicted in Figs. 1 to 4. There was no 
change or difference in the X-axis intercept point for 
end-systolic elastance (prebypass 6.9 _+ 0.1, postby- 
pass 6.8 _+ 0.2) or PRSW (prebypass 10.4 _+ 0.2, 
postbypass 10.1 _+ 0.2) between prebypass (baseline) 
and postbypass values in any experimental group. 
Therefore the change in slope of end-systolic elas- 
tance and PRSW can be interpreted to express 
variability in the contractile state of the myocardium 
compared with control values. Adding magnesium 
to a hypocalcemic ardioplegic solution (groups I
and II) had no statistically significant effect on 
myocardial function, inasmuch as both groups had 
complete preservation of postbypass ystolic func- 
tion (101% _+ 2% vs 104% _+ 3%) and PRSW 
(102% _+ 2% vs 100% _+ 1%) and a minimal 
increase in diastolic stiffness (159% _+ 2% vs 153% 
_+ 12%). Conversely, using a normocalcemic car- 
dioplegic solution without magnesium supplementa- 
tion (group III) resulted in poorer results than those 
obtained with magnesium supplementation (group 
IV): a marked reduction in postbypass systolic func- 
tion (49% _+ 4% vs 101% + 1%; p < 0.0001), 
increased iastolic stiffness (276% _+ 9% vs 162% +_ 
3%;p < 0.0001), and decreased PRSW (53% _+ 3% 
vs 102% _+ 2%; p < 0.0001). Use of magnesium- 
enriched cardioplegic solution, by contrast, resulted 
in complete functional recovery. There were no 
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Fig. 2. LV diastolic compliance as measured by the end-diastolic pressure volume relationship and 
expressed as percent increased stiffness compared with baseline values. Only a minimal increase in diastolic 
stiffness is observed in hearts protected with hypocalcemic cardioplegic solutions independent of the 
presence of magnesium. A marked increase in diastolic stiffness is observed in hearts protected with a 
normocalcemic solution without magnesium enrichment. Conversely, when magnesium is added to the 
normocalcemic cardioplegic solution, diastolic ompliance is maintained. *p < 0.001. 
statistically significant differences (p > 0.2) in CVR 
among groups I, II, and IV (Fig. 4). In contrast, 
there was a marked increase in CVR in hearts 
receiving a normocalcemic ardioplegic solution 
without magnesium enrichment (group III), imply- 
ing that these hearts had sustained a vascular injury. 
Because cardioplegic solution was delivered over 
time at a given pressure, this also resulted in a lower 
total dose of cardioplegic solution in these hearts. 
Tissue studies. Endocardial tissue results are 
summarized in Table III. In contrast o the func- 
tional results, magnesium supplementation f a 
hypocalcemic cardioplegic solution (group II) re- 
sulted in better preservation of ATP levels (F = 
9.06, p = 0.008). Conversely, use of a normocal- 
cemic cardioplegic solution without magnesium 
(group III) significantly depressed ATP levels as a 
result of a calcium-mediated injury. This fall in 
myocardial ATP was prevented by adding magne- 
sium to the normocalcemic solution (group IV), 
implying that magnesium blocks the deleterious 
effects of calcium. The ATP/ADP ratio, which 
reflects the ability of the mitochondria to phos- 
phorylate ADP to ATP, was markedly reduced 
when a normocalcemic cardioplegic solution with- 
out magnesium (group IV) was used, further 
suggesting mitochondrial damage as a result of 
high calcium levels (F = 125, p < 0.0001). This 
group also had the highest percentage of myocar- 
dial water of any experimental group, indicating 
the greatest degree of myocardial cell damage 
(F = 68.4, p < 0.0001). 
Discussion 
This study demonstrates that in a clinically rele- 
vant intact animal model simulating conditions in 
the operating room, (1) magnesium does not signif- 
icantly alter the cardioprotective effects of a hy- 
pocalcemic eardioplegic solution, (2) a normocalce- 
mic cardioplegic solution is detrimental to neonatal 
myocardium subjected to a previous hypoxic stress, 
and (3) adding magnesium to a normocaleemie 
cardioplegic solution prevents the deleterious effects 
of calcium. 
Intraeellular accumulation of calcium during isch- 
emia and reperfusion has been associated with 
cellular injury. 1-3' 12, 13 Several mechanisms of injury 
have been proposed, including increased ATP use 
through activation of calcium-dependent ATPases; 
impaired ATP synthesis resulting from mitochon- 
drial damage from calcium uptake; activation of 
numerous calcium-dependent degradative enzymes 
such as proteases, lipases, and phospholipases; and 
calcium enhancement of various free radical-medi- 
ated reactions. 2' 14, 15 The neonatal heart may be 
more susceptible to a calcium-mediated cellular 
injury because the sarcoplasmic reticulum of the 
immature myocardium has a diminished capacity to 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 114, Number 6 
Kronon et al. 1015 
100, 
% Recovery 
50, 
O. 
, - I . -  
Hypocalcemic 
No Mg .2 
Mg *2 
w 
¢/ / /•  
¢ / / /~  
N 
. ® 
I / / /~  
D 
;////, 
r . ,¢ / /~  
¢ / / /~  
r J / f~  
F j f /~  
~' / / / J  
¢/ / /~  
¢ / / /~  
r / / / /  
Normocalcemic 
Fig. 3. Overall LV myocardial function measured by PRSW and expressed as percent recovery compared 
with baseline values. Global myocardial function is completely preserved, independent ofthe presence of 
magnesium, in hearts protected with a hypocalcemic cardioplegic solution. In hearts protected with a 
normocalcemic cardioplegic solution, there is marked loss of global myocardial function in the absence of 
magnesium enrichment. Conversely, magnesium enrichment offsets the detrimental effects of high-calcium 
cardioplegic solution, preserving PRSW. *p < 0.001. 
sequester calcium and because of different charac- 
teristics of the calcium transport system. 2'3 
Despite the fact that magnesium has been shown 
to prevent he intracellular accumulation of calcium 
during global myocardial ischemia, few studies have 
examined whether magnesium can prevent he del- 
eterious effects of calcium in cardioplegic solu- 
tions.3, 5, 7, 15, 16 High magnesium concentration has 
been suggested to inhibit calcium entry into the cell 
by displacing calcium from binding sites in the 
sarcolemmal membrane (1-type calcium channels) 
and by hyperpolarization f the sarcolemmal mem- 
brane.7, 15, 17 It has also been postulated that extra- 
cellular magnesium, when supplied before global 
myocardial ischemia, acts by raising cytosolic mag- 
nesium concentrations, thereby reducing the release 
of calcium from the sarcoplasmic reticulum. 15' 17 
Finally, replenishing magnesium in ischemic hearts 
may diminish the depletion of ATP stores, thereby 
protecting the phosphorylation function of mito- 
chondria during and after reperfusion. 5' 15 
An increasing number of infants with cyanotic 
congenital heart disease are undergoing primary 
surgical repair. Although this may be preferable to 
palliation, it subjects the immature hypoxic heart to 
CPB and high levels of oxygen, which produce an 
unintended reoxygenation i jury. 1'8'9' 18 This oxy- 
gen-derived free radical-mediated injury results in 
myocardial depression and may explain why impair- 
ment of ventricular function is common after appar- 
ently satisfactory surgical correction of cyanotic 
congenital defects. 13' 19-21 Despite the prevalence of 
this condition in the pediatric population, few stud- 
ies of pediatric myocardial protection have included 
hypoxic hearts, and none have investigated the 
relationship between calcium and magnesium in 
cardioplegic solutions. Including these hearts is ex- 
tremely important, because hypoxia may profoundly 
alter the neonatal myocardium, thus influencing the 
effects of a given cardioplegic solution, l' 3, 22, 23 We 
therefore xamined the interaction of calcium and 
magnesium levels in cardioplegic solutions in neo- 
natal hearts using a clinically relevant stress (hy- 
poxic) model that mimics conditions of the operat- 
ing room. 
Hearts protected with a hypocalcemic cardiople- 
gic solution had complete preservation of myocar- 
dial function regardless of the presence or absence 
of magnesium (see Figs. 1 to 3). This is in accor- 
dance with our previous findings showing that ade- 
quate myocardial protection in the hypoxically 
stressed heart is provided by a hypocalcemic car- 
dioplegic solution. 1 However, ATP levels were 
slightly higher in hearts protected with magnesium- 
enriched hypocalcemic ardioplegia, suggesting a
possible benefit o magnesium, even in the presence 
of low levels of calcium in the cardioplegic solution. 
Calcium can increase myocardial wall tension even 
during potassium arrest; hence calcium is a deter- 
minant of energy requirements during cardioplegic 
arrest.7, 15, 24 Therefore, by blocking calcium entry 
during ventricular asystole, magnesium may lower 
metabolic demands by decreasing wall tension, thus 
improving ATP levels. The ischemic (crossclamp) 
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Fig. 4. CVR measured uring each cardioplegic nfusion. There is no difference in CVR in hearts 
protected with a hypocalcemic solution or a normocalcemic solution enriched with magnesium. Conversely, 
there is a marked rise in CVR when a normocalcemic cardioplegic solution was infused in the absence of 
magnesium enrichment, indicating a coronary vascular injury. *p < 0.001. 
time was relatively short in this study, and the 
neonatal myocardium may be more tolerant of 
ischemia than the adult myocardium. 3' 13 Because 
the reperfusion injury depends on the duration of 
ischemia, this may have accounted for the lack of 
greater improvement seen with magnesium enrich- 
ment of hypocalcemic solutions. 
Subjecting the hypoxically stressed neonatal heart 
to a normocalcemic cardioplegic solution pro- 
foundly altered the effect of magnesium supplemen- 
tation. Hypoxic neonatal hearts ustain a significant 
cellular injury when protected with a normocalcemic 
cardioplegic solution. 1 This injury is manifested by 
depression in postbypass myocardial and vascular 
dysfunction. In contrast, adding magnesium to a 
normocalcemic solution not only protects the heart 
from further damage, but facilitates repair of the 
injury caused by hypoxia nd reoxygenation, result- 
ing in complete preservation of myocardial and 
vascular endothelial cell function (see Figs. 1 to 4). 
This implies that magnesium offsets the detrimental 
effects of high calcium concentrations in cardiople- 
gic solutions. 
Vascular function was determined by measuring 
CVR during each infusion of cardioplegic solution 
when the heart was arrested and the flow rate and 
infusion pressure had reached a steady state. Al- 
though the myocardial metabolic demands and thus 
CVR may change between warm and cold cardio- 
plegia, they should be identical for each heart at any 
given temperature. This is precisely what was seen in 
hearts protected hypocalcemic cardioplegia or nor- 
mocalcemic ardioplegia with magnesium enrich- 
ment. In contrast, there was a marked increase in 
CVR during each cardioplegic infusion in hearts 
protected with a normocalcemic solution without 
added magnesium (Fig. 4) This appears to reflect a 
derangement in vascular function resulting from 
higher calcium levels without he protective benefit 
of magnesium enrichment. This increased CVR may 
have also resulted in a less homogeneous distribu- 
tion of cardioplegic solution, as well as a lower 
volume of solution infused, thereby further compro- 
mising myocardial protection during cardiac arrest. 
The hypoxic heart has been shown both clinically 
and experimentally to have an increased susceptibil- 
ity to ATP depletion during surgically induced isch- 
emia.23, 25 Elevated calcium concentration during 
ischemia accelerates the breakdown of ATP by 
activation of calcium-dependent ATPases. 2' 15, 26 
This energy depletion may further impair ATP- 
dependent mechanisms that maintain calcium ho- 
meostasis. Postbypass tissue ATP levels seem to 
support his hypothesis. In both hypocalcemic car- 
dioplegia groups, ATP levels and the ATP/ADP 
ratio were preserved (see Table III). Conversely, 
endocardial ATP levels were markedly reduced in 
hearts protected with normocalcemic cardioplegia 
without added magnesium (group IV). In addition, 
the ATP/ADP ratio also fell in this group, which 
seems to indicate that there is indeed some mito- 
chondrial damage resulting in a decreased ability to 
convert ADP to ATP. However, high-energy phos- 
phates and mitochondrial function were preserved 
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in hearts protected with a magnesium-enriched nor- 
mocalcemic cardioplegic solution, implying that 
magnesium limits the detrimental effects of high 
calcium concentrations. Because low postischemic 
ATP levels in infants correlate with poor postoper- 
ative ventricular function, these findings, along with 
the functional data, suggest hat magnesium-free 
normocalcemic ardioplegia provides inadequate 
myocardial protection in hypoxic hearts. Indeed, 
these findings parallel those seen clinically in pa- 
tients with the tetralogy of Fallot, in whom ATP 
levels are significantly depressed and ventricular 
function is often decreased after apparently success- 
ful Surgical correction. 2°' 21 
Although our model of acute hypoxia does not 
allow for the chronic adaptive changes that may 
occur in cyanotic newborn infants, it does subject 
the heart tO a clinically relevant stress. Including 
stressed hearts in cardioplegia investigation is ex- 
tremely important, because these hearts are more 
vulnerable to ischemia nd more sensitive to meth- 
ods of myocardial protectionJ' 12 Several studies 
have documented a similar oxygen-mediated injury 
with reoxygenation f the chronically hypoxic infant, 
and we recently reported an identical injury in 21 
cyanotic infants using the same biochemical param- 
eters as used in our acute experimental stud- 
ies.8, 9, 18, 27, 28 Indeed, these studies uggest that the 
injury after chronic cyanosis may be even more 
severe than after acute hypoxia. Our experimental 
model of acute hypoxia does not cause significant 
depletion O f ATP stores. 9' 29 Conversely, chronically 
cyanotic hearts may be predisposed to accelerated 
depletion of these high-energy compounds during 
periods of increased myocardial oxygen de- 
mands j3, 3o, 32 Because the presence of magnesium 
has been shown to improve metabolic and func- 
tional recovery after ischemia by helping to prevent 
ATP depletion, this further suggests that magne- 
sium-enhanced cardioplegic solutions should be 
used in cyanotic infants. 3' 5, 15 
Magnesium has been shown to improve myo- 
cardial protection by preventing the intracellular 
accumulation of calcium during isChemia and re- 
perfusion.3, 5  6, 25 This study supports this effect. 
However, the improvement seen in hypoxic hearts 
protected with hypocalcemic cardioplegia cannot be 
explained by this mechanism, because all piglets had 
complete preservation of preoperative myocardial 
function regardless of the presence of magnesium in
the solution. Therefore the question of whether 
magnesium supplementation is necessary when us- 
Table III. Endocardial tissue 
A TP A TP/ADP Myocardial 
Group (txg/gm dry wt) ratio water (%) 
Low Ca+2/no Mg +z 15.1 _+ 0.7 4.2 _+ 0.2 78.8 _+ 0.6 
(group I) 
Low Ca+2/Mg +z 17.5 _+ 0.4* 4.3 _+ 0.6 78.9 _+ 0.2 
(group II) 
High Ca+a/no Mg +2 12.1 + 0.9* 2.3 + 0.2* 80.0 _+ 0.2* 
(group III) 
High Ca+2/Mg +2 15.6 ± 0.3 4.1 + 0.3 78.9 _+ 0.3 
(group IV) 
Ca +2, Calcium; Mg +2, magnesium. 
*p < 0.05 versus all groups. 
ing a hypocalcemic cardioplegic solution remains 
unanswered. In clinical practice, however, it is more 
difficult to precisely regulate the cardioplegic al- 
cium concentration because of transient variables 
such as pH, temperature, plasma volume, and dif- 
ferent bypass calcium concentrations. As a result, 
the patient is at risk of exposure to higher than 
intended calcium levels. This elevated calcium con- 
tent cannot be safely prevented by further decreas- 
ing the already minimal (0.2 to 0.4 mmol/L) ionized 
calcium level because of the risk of causing a 
calcium paradox. The addition of magnesium ay 
solve this dilemma by allowing for the safe use of 
higher cardioplegic alcium concentrations. Fur- 
thermore, even in the presence of hypocalcemic 
cardioplegic solutions, other inhibitors of calcium 
entry (i.e., calcium channel blockers) have been 
shown to further enhance myocardial protection by 
limiting intracellular calcium accumulation; and in 
this study, ATP levels were highest when magne- 
sium enrichment was combined with hypocalcemic 
solutions (group 1). Therefore we will continue to 
advocate the use of magnesium in hypocalcemic 
cardioplegic solutions until this issue is further 
investigated. 
In summary, this study demonstrates that in a 
clinically relevant model, magnesium does not sig- 
nificantly alter the cardioprotective effects of a 
hypocalcemic cardioplegic solution in hypoxic hearts 
subjected to a short ischemic interval. Use of a 
normocalcemic cardioplegic solution is detrimental 
to the hypoxic neonatal myocardium, resulting in 
poor myocardial protection. In contrast, magnesium 
enrichment prevents the deleterious effects of nor- 
mocalcemic cardioplegic solutions and thus provides 
markedly superior myocardial protection. Inasmuch 
as many pediatric heart surgeons use moderate 
calcium concentrations in their cardioplegic solu- 
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tions, this study suggests that the routine addition of 
magnesium to cardioplegic solutions may improve 
myocardial protection in the cyanotic infant. 
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Discussion 
Dr. Tirone E. David (Toronto, Or~tario, Canada). 
Dr. Allen, is magnesium equally important for the mature 
heart? 
Dr. Allen. Yes. I believe magnesium isvery important in 
both the immature and the mature heart. We now add 
magnesium to all our cardioplegic solutions and have 
excellent results in more than 300 pediatric and adult 
patients. 
Dr. David. Is it important only with blood cardioplegia? 
Dr. Allen. I firmly believe magnesium supplementation 
is important in both crystall0id and blood cardioplegic 
solutions. Dr. Hearse demonstrated years ago that adding 
magnesium to St. Thomas' Hospital solution improved 
myocardial protection, and other investigators have found 
similar benefits with blood cardioplegia. So far as I know, 
however, this is the first time magnesium has been shown 
to be beneficial in the neonatal heart and to counteract 
the detrimental effects of normocalcemic cardioplegia. 
Dr. Sidney Levitsk 3, (Boston, Mass.). We have been 
using magnesium added to normocalcemic blood car- 
dioplegic solutions both experimentally and clinically. 
What is your hypothesis to explai n your observation that 
ATP is decreased without the use of magnesium? Does 
magnesium added to cardioplegia have an effect on ATP 
synthesis or breakdown during surgically induced myocar- 
dial ischemia? 
Dr. Allen. I am well aware of your extensive work in this 
field. You are partially responsible for stimulating my 
interest in this area of research. I believe magnesium 
limits extracellular calcium entry an d reduces the release 
of calcium from the sarcoplasmic reticulum. This lowers 
intracellular calcium levels and helps preserve ATP by two 
mechanisms. First, it prevents activation of calcium-de- 
pendent ATPases. Second, calcium increases myocardial 
wall stress even during potassium arrest. If wall stress is 
decreased by limiting intracellular calcium, then ATP use 
is minimized, resulting in improved myocardial preserva- 
tion and higher ATp levels. 
Dr. D. Glenn Pennington (Winston Salem, N.C.). Do 
you think this effect OCCURS merely in a hypoxic heart? For 
example, in an infant without cyanotic heart disease, do 
these same rules apply? 
Dr. Allen. On the basis of numerous tudies from our 
laboratory, as well as those of other investigators, we now 
add magnesium to all our cardioplegic solutions. As to your 
question concerning specifically noncyanotic infants, I be- 
lieve magnesium supplementation is beneficial in all patients 
because most patients undergoing surgery do not have 
"normal" hearts. Those infant hearts not stressed by hypoxia 
are usually subjected to pressure or volume overload as a 
result of their cardiac defect. Similarly, most adult hearts are 
stressed by either hypertrophy or ischemia. Inasmuch as we 
therefore operate on very few "normal" hearts, either in 
adults or in children, I believe magnesium enrichment 
should always be used, because beneficial effects of magne- 
sium are most likely to be seen in stressed hearts. 
